Volume 5, Issue 6
Editorialp. 531–533
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Author(s): Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorialp. 535–537
The challenges of conducting clinical trials for neglected tropical diseases
Author(s): Maria P Rebollo, Moses J Bockarie
Interviewp. 539–542
Clinical trial recruitment in the information age
Author(s): Tom Dorsett, Stella Bennett
Drug Evaluationp. 543–549
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
Author(s): K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluationp. 551–559
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Author(s): Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluationp. 561–571
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Author(s): Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Clinical Trail Perspectivep. 573–583
Is social media suitable for patient recruitment?
Author(s): Wolfgang Eglmeier
Clinical Trail Perspectivep. 585–597
Monitoring randomized clinical trials in Africa; pragmatic approaches and experiences from HIV trials
Author(s): Margaret J Thomason, Moira J Spyer1, Nicola Joffe1, Justine Boles, Andy Burke, Helen C Wilkes & Mary Rauchenberger
Clinical Trail Methodologyp. 599–612
Clinical trial end points relevant to patients and society for rare cancers
Author(s): Shelize Khakoo, Alexandros Georgiou & Ian Chau
